Skip to main content

Table 4 Adjusted screening performance measurements with 95% confidence intervals using GEE to account for correlations between mammograms of the same woman and to correct for the confounders percent dense volume and breast volume

From: Influence of breast compression pressure on the performance of population-based mammography screening

 

Group 1

Group 2

Group 3

Group 4

Group 5

Recall/1000

26.1

(24.0–28.5)

20.8

(19.1–22.6)

22.0

(20.3–23.9)

21.0

(19.3–22.8)

22.2

(20.3–24.3)

False positives/1000

20.0

(18.1–22.1)

14.8

(13.4–16.4)

15.1

(13.7–16.6)

15.2

(13.8–16.8)

16.2

(14.6–18.0)

Screen-detected cancers/1000

6.1

(5.2–7.2)

5.9

(5.0–6.9)

6.9

(6.0–8.0)

5.7

(4.9–6.7)

5.9

(4.9–7.0)

Interval cancers/1000

1.3

(0.9–1.8)

1.6

(1.2–2.2)

1.6

(1.2–2.1)

2.2

(1.7–2.8)

2.3

(1.7–3.0)

Program sensitivity (%)*

82.0

(75.6–87.0)

77.1

(70.9–82.4)

79.8

(74.2–84.4)

71.1

(64.5–79.8)

70.8

(63.6–77.1)

12 month sensitivity (%)**

90.1

(84.4–93.9)

92.0

(87.2–95.1)

93.9a

(89.7–96.5)

87.2

(81.3–91.4)

84.3a

(77.3–89.4)

Specificity (%)

98.0a,b,c

(97.8–98.2)

98.5a

(98.3–98.7)

98.5b

(98.3–98.6)

98.5c

(98.3–98.6)

98.4

(98.2–98.5)

Positive predictive value (%)

23.5

(20.2–27.3)

28.7

(25.0–32.7)

31.5

(27.9–35.3)

27.3

(23.7–31.1)

26.7

(22.9–30.8)

  1. Pair-wise testing was applied on the sensitivity and specificity measurements and each subscript letter denotes a pair of pressure categories whose measurements differ significantly from each other
  2. The Tukey method was used for correction for multiple testing and a p value below 0.05 was considered significant
  3. The programm sensitivity (*) is calculated with all interval cancers, the 12-month sensitivity (**) is calculated with the interval cancers that were detected within 12 months after the examination